PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma.

Josine Quispel-Janssen,Vincent van der Noort, Jeltje F de Vries, Marion Zimmerman,Ferry Lalezari,Erik Thunnissen,Kim Monkhorst,Robert Schouten, Laurel Schunselaar,Maria Disselhorst,Houke Klomp,Koen Hartemink,Sjaak Burgers,Wieneke Buikhuisen,Paul Baas

Journal of Thoracic Oncology（2018）

引用 187|浏览18

暂无评分

摘要

Single agent nivolumab has meaningful clinical efficacy and a manageable safety profile in pretreated patients with mesothelioma. PD-L1 expression does not predict for response in this population.

查看译文

关键词

Mesothelioma,Immunotherapy,Programmed death ligand 1,Nivolumab,Checkpoint inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要